Definium Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
Definium Therapeutics, Inc. (DFTX) reported Increase (Decrease) in Accrued Liabilities of $9.85 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- Definium Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $6.85M, a 127.83% increase year-over-year.
- Definium Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was $2.99M.
- Definium Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $923.00K, a 75.62% decline year-over-year.
- Definium Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $3.36M, a 225.83% increase year-over-year.
- Definium Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $5.96M, a 92.01% increase from fiscal 2024.
- Definium Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $3.10M, a 41.65% decline from fiscal 2023.
- Definium Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $5.32M.
- Definium Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$416.00K, a 108.98% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 7 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $6.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.85M 10-Q · filed 2026-08-06 | $10.77M derived: sum of 3 quarters · filed 2026-08-06 | $14.13M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $2.99M 10-Q · filed 2026-05-07 | $3.92M derived: sum of 2 quarters · filed 2026-05-07 | $7.27M derived: sum of 3 quarters · filed 2026-05-07 | $10.28M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $923.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.28M derived: sum of 2 quarters · filed 2026-02-26 | $7.29M derived: sum of 3 quarters · filed 2026-08-06 | $5.96M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $3.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $6.36M derived: sum of 2 quarters · filed 2026-08-06 | $5.04M 10-Q · filed 2025-11-06 | $8.82M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.68M 10-Q · filed 2026-08-06 | $5.46M derived: sum of 3 quarters · filed 2026-08-06 | $6.50M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$1.33M 10-Q · filed 2026-05-07 | $2.46M derived: sum of 2 quarters · filed 2026-05-07 | $3.49M derived: sum of 3 quarters · filed 2026-05-07 | $4.48M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.82M derived: sum of 2 quarters · filed 2026-02-26 | $5.81M derived: sum of 3 quarters · filed 2026-02-26 | $3.10M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.02M derived: sum of 2 quarters · filed 2025-11-06 | -$683.00K 10-Q · filed 2025-11-06 | $893.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $990.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$1.71M 10-Q · filed 2025-07-31 | -$137.00K derived: sum of 3 quarters · filed 2025-07-31 | -$284.00K derived: sum of 4 quarters · filed 2025-07-31 | |
| 2024-03-31 | -$2.70M 10-Q · filed 2025-05-08 | -$1.13M derived: sum of 2 quarters · filed 2025-05-08 | -$1.27M derived: sum of 3 quarters · filed 2025-05-08 | $1.91M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $1.43M derived: sum of 2 quarters · filed 2025-03-06 | $4.62M derived: sum of 3 quarters · filed 2025-03-06 | $5.32M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$147.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.04M derived: sum of 2 quarters · filed 2024-11-07 | $3.74M 10-Q · filed 2024-11-07 | $2.70M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $3.89M 10-Q · filed 2024-08-13 | $2.85M derived: sum of 3 quarters · filed 2024-08-13 | $2.68M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $703.00K 10-Q · filed 2024-05-08 | -$335.00K derived: sum of 2 quarters · filed 2024-05-08 | -$505.00K derived: sum of 3 quarters · filed 2024-05-08 | -$707.00K derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | -$1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$1.21M derived: sum of 2 quarters · filed 2024-02-28 | -$1.41M derived: sum of 3 quarters · filed 2024-02-28 | -$416.00K 10-K · filed 2024-02-28 | |
| 2022-09-30 | -$170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$372.00K derived: sum of 2 quarters · filed 2023-11-02 | $622.00K 10-Q · filed 2023-11-02 | $8.14M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $792.00K 10-Q · filed 2023-08-03 | $8.31M derived: sum of 3 quarters · filed 2023-08-03 | $2.84M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $994.00K 10-Q · filed 2023-05-04 | $8.52M derived: sum of 2 quarters · filed 2023-05-04 | $3.05M derived: sum of 3 quarters · filed 2023-05-04 | $4.25M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $2.05M derived: sum of 2 quarters · filed 2023-03-09 | $3.25M derived: sum of 3 quarters · filed 2023-03-09 | $4.63M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$5.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$4.27M derived: sum of 2 quarters · filed 2022-11-10 | -$2.89M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.58M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $1.38M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | -$242.00K 10-K · filed 2022-03-28 | ||||
| 2019-12-31 | $744.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |